Stefan M. Nidorf
University of Western Australia
Internal medicineCardiologyRandomized controlled trialAdverse effectClinical endpointColchicineStatinInflammationInflammasomeAcute coronary syndromeCholesterolHeart failureCoronary artery diseaseDiseaseGoutIn patientCreatine kinaseIncidence (epidemiology)Myocardial infarctionClinical trialMedicineRelative risk
20Publications
10H-index
1,058Citations
Publications 21
Newest
#1Tjerk S.J. Opstal (Radboud University Nijmegen)H-Index: 4
#2Aernoud T.L. Fiolet (UU: Utrecht University)H-Index: 6
Last. Eugène A. van BeekH-Index: 1
view all 0 authors...
Abstract null null Background null Colchicine reduces risk of cardiovascular events in patients post–myocardial infarction and in patients with chronic coronary disease. It remains unclear whether this effect is related to the time of onset of treatment following an acute coronary syndrome (ACS). null null null Objectives null This study investigates risk for major adverse cardiovascular events in relation to history and timing of prior ACS, to determine whether the benefits of colchicine are co...
1 CitationsSource
Introduction: Recurrent event rates after myocardial infarction (MI) remain unacceptably high, in part because of the continued growth and destabilization of residual coronary atherosclerotic plaques, which may occur despite lipid-lowering therapy. Inflammation is an important contributor to this ongoing risk. Recent studies have shown that the broad-acting anti-inflammatory agent, colchicine, may reduce adverse cardiovascular events in patients post-MI, although the mechanistic basis for this r...
Source
#1Aernoud T.L. Fiolet (University Medical Center Utrecht)H-Index: 6
#2Tjerk S.J. Opstal (Radboud University Nijmegen)H-Index: 4
Last. Jan H. Cornel (Radboud University Nijmegen)H-Index: 66
view all 9 authors...
1 CitationsSource
#1Aernoud T.L. Fiolet (University Medical Center Utrecht)H-Index: 6
#2Tjerk S.J. OpstalH-Index: 4
Last. Jan H. CornelH-Index: 66
view all 14 authors...
AIMS Recent randomized trials demonstrated a benefit of low-dose colchicine added to guideline-based treatment in patients with recent myocardial infarction or chronic coronary disease. We performed a systematic review and meta-analysis to obtain best estimates of the effects of colchicine on major adverse cardiovascular events (MACE). METHODS AND RESULTS We searched the literature for randomized clinical trials of long-term colchicine in patients with atherosclerosis published up to 1 September...
16 CitationsSource
Source
Abstract Background Evidence from a recent trial has shown that the antiinflammatory effects of colchicine reduce the risk of cardiovascular events in patients with recent myocardial infarction, bu...
261 CitationsSource
#1Stefan M. Nidorf (SCGH: Sir Charles Gairdner Hospital)H-Index: 10
#2Aernoud T.L. Fiolet (UU: Utrecht University)H-Index: 6
Last. George S. Abela (MSU: Michigan State University)H-Index: 35
view all 3 authors...
Abstract Reducing the residual risk of cardiovascular events (CV) in patients with atherosclerosis continues to be a challenge. Thus, understanding how cholesterol spontaneously self assembles into metastable structures that evolve into flat plate cholesterol crystals (CCs) in atherosclerotic plaque, and why they fundamentally change the nature of the disease provides a paradigm for the development of additional therapies. Specifically, flat plate CCs that form within lysosomes of macrophages ma...
9 CitationsSource
Abstract Background Because patients with stable coronary artery disease are at continued risk of major atherosclerotic events despite effective secondary prevention strategies, there is a need to continue to develop additional safe, effective and well-tolerated therapies for secondary prevention of cardiovascular disease. Rationale and Design The LoDoCo (Low Dose Colchicine) pilot trial showed that the anti-inflammatory drug colchicine 0.5 mg once daily appears safe and effective for secondary ...
33 CitationsSource
#2Stefan M. NidorfH-Index: 10
Last. Jan H. CornelH-Index: 66
view all 4 authors...
Abstract Purpose Disease management of stable coronary artery disease consists of controlling hemostasis and lipid regulation. No treatment strategies preventing plaque erosion or rupture are yet available. Cholesterol crystal–induced inflammation leading to plaque destabilization is believed to be an important factor contributing to plaque instability and might well be amenable to treatment with anti-inflammatory drugs. Colchicine has anti-inflammatory properties with the potential to address b...
16 CitationsSource
#1Stefan M. Nidorf (Harry Perkins Institute of Medical Research)H-Index: 10
#2Peter L. ThompsonH-Index: 54
Abstract Purpose Colchicine is a widely available, inexpensive drug with a range of antiinflammatory properties that may make it suitable for the secondary prevention of atherosclerosis. This review examines how past and contemporary approaches to antiinflammatory therapy for atherosclerosis have led to a better understanding of the nature of the disease and sets out the reasons why colchicine has the potential to become a cornerstone therapy in its management. Methods We performed a literature ...
33 CitationsSource